PE20240767A1 - Compuestos, composiciones y metodos para el tratamiento de trastornos - Google Patents

Compuestos, composiciones y metodos para el tratamiento de trastornos

Info

Publication number
PE20240767A1
PE20240767A1 PE2023002860A PE2023002860A PE20240767A1 PE 20240767 A1 PE20240767 A1 PE 20240767A1 PE 2023002860 A PE2023002860 A PE 2023002860A PE 2023002860 A PE2023002860 A PE 2023002860A PE 20240767 A1 PE20240767 A1 PE 20240767A1
Authority
PE
Peru
Prior art keywords
optionally substituted
group
methods
compound
formula
Prior art date
Application number
PE2023002860A
Other languages
English (en)
Spanish (es)
Inventor
Yingzhi Bi
Ken Carson
Geraldine Cirillo Harriman
Graham A B Hone
Rajiv Gandhi Govindaraj
Rajiah Aldrin Denny
David J Diller
Original Assignee
Hotspot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hotspot Therapeutics Inc filed Critical Hotspot Therapeutics Inc
Publication of PE20240767A1 publication Critical patent/PE20240767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2023002860A 2021-04-16 2022-04-15 Compuestos, composiciones y metodos para el tratamiento de trastornos PE20240767A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US202163281493P 2021-11-19 2021-11-19
PCT/US2022/025083 WO2022221704A1 (en) 2021-04-16 2022-04-15 Compounds, compositions and methods of treating cancer

Publications (1)

Publication Number Publication Date
PE20240767A1 true PE20240767A1 (es) 2024-04-17

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002860A PE20240767A1 (es) 2021-04-16 2022-04-15 Compuestos, composiciones y metodos para el tratamiento de trastornos

Country Status (14)

Country Link
US (1) US20240228482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323358A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514339A (cg-RX-API-DMAC7.html)
KR (1) KR20240037184A (cg-RX-API-DMAC7.html)
AU (1) AU2022256514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021068A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215395A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003068A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015484A2 (cg-RX-API-DMAC7.html)
IL (1) IL307732A (cg-RX-API-DMAC7.html)
MX (1) MX2023012245A (cg-RX-API-DMAC7.html)
PE (1) PE20240767A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309023A (cg-RX-API-DMAC7.html)
WO (1) WO2022221704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
US20250042896A1 (en) * 2021-10-29 2025-02-06 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Polycyclic compound as cbl-b inhibitor
US12187709B2 (en) 2021-11-05 2025-01-07 Genentech, Inc. Lactams as CBL-B inhibitors selective over C-CBL
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523682A (ja) * 2022-07-12 2025-07-23 ホットスポット セラピューティクス インコーポレイテッド 複素環式化合物の調製方法
KR20250085707A (ko) * 2022-07-12 2025-06-12 핫스팟 세라퓨틱스, 인크. Cbl-b 조절제로서의 트리아진 유도체의 고체 형태
JP2025523058A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
CN119630662A (zh) * 2022-07-18 2025-03-14 英矽智能科技知识产权有限公司 Cbl-b抑制剂及其应用方法
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
US20260193251A1 (en) 2022-11-16 2026-07-09 Pfizer Inc. Substituted Bicyclic Pyridone Derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
EP4653436A1 (en) * 2023-01-19 2025-11-26 Guangzhou Yufan Nantu Biotechnologies Co., Ltd Heterocyclic compounds, preparation method therefor and use thereof
WO2024153246A1 (zh) * 2023-01-20 2024-07-25 海南先声再明医药股份有限公司 取代的三环化合物及其应用
WO2024227436A1 (en) * 2023-05-04 2024-11-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025067342A1 (zh) * 2023-09-27 2025-04-03 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
US10968216B2 (en) * 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3733667B1 (en) * 2017-12-26 2024-06-12 Sumitomo Chemical Company, Limited Heterocyclic compounds and noxious arthropod control agent containing same
KR102922115B1 (ko) * 2019-04-09 2026-02-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
CA3294689A1 (en) * 2019-06-26 2026-03-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
KR20250085707A (ko) * 2022-07-12 2025-06-12 핫스팟 세라퓨틱스, 인크. Cbl-b 조절제로서의 트리아진 유도체의 고체 형태
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
JP2025523682A (ja) * 2022-07-12 2025-07-23 ホットスポット セラピューティクス インコーポレイテッド 複素環式化合物の調製方法
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523058A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置

Also Published As

Publication number Publication date
KR20240037184A (ko) 2024-03-21
WO2022221704A1 (en) 2022-10-20
JP2024514339A (ja) 2024-04-01
AU2022256514A1 (en) 2023-10-19
EP4323358A1 (en) 2024-02-21
TW202309023A (zh) 2023-03-01
CA3215395A1 (en) 2022-10-20
MX2023012245A (es) 2024-03-11
CO2023015484A2 (es) 2023-11-30
BR112023021068A2 (pt) 2024-01-23
IL307732A (en) 2023-12-01
US20240228482A1 (en) 2024-07-11
CL2023003068A1 (es) 2024-05-03

Similar Documents

Publication Publication Date Title
DOP2021000254A (es) Compuestos de pirrolidina
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
AR118707A1 (es) Inhibidores de la proteasa del vih
CL2024003450A1 (es) Compuestos y usos de estos
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
PE20250155A1 (es) Derivados de la urea que pueden ser utilizados para tratar el cancer
PE20200009A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
ECSP23020167A (es) Inhibidores de apol1 y métodos para usar los mismos
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
UY40235A (es) Compuestos de heteroarilo para el tratamiento del dolor
AR133953A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CO2021017202A2 (es) Compuestos tricíclicos
MX2025002817A (es) Compuestos para el tratamiento del cancer
MX2023003731A (es) Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos.
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
DOP2025000009A (es) Inhibidores de acc novedosos
MX2022002839A (es) Nuevo compuesto heterocíclico aromático tricíclico, método de preparación del mismo, composición farmacéutica y aplicación del mismo.
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
AR130747A1 (es) Compuestos novedosos derivados de triciclo y usos de los mismos